Core Viewpoint - The announcement of a strategic partnership between InSilico Medicine (英矽智能) and HengTai Biopharma for the joint development of ISM8969, a novel NLRP3 inhibitor aimed at treating central nervous system diseases, has positively impacted the company's stock price, leading to a nearly 5% increase in early trading [1] Group 1: Partnership Details - InSilico Medicine has entered into a collaboration agreement with HengTai Biopharma to accelerate the global development of ISM8969 [1] - The agreement grants HengTai Biopharma 50% rights for research, development, registration, production, and commercialization of ISM8969 worldwide [1] Group 2: Financial Implications - InSilico Medicine is set to receive over HKD 500 million in upfront and milestone payments, including an expected upfront payment of HKD 78 million to be paid within 30 days of the agreement's effective date [1]